VAXIL

Creating the ideal immunotherapy

Inducing a Broad
Response

Learn More

universally
Applicable

Learn More

Overcoming
Cancer Resistance

Learn More

Harnessing Potent
Immune Response

Learn More

Tumor
Specific

Learn More

Expression on
Cancer Stem Cells

Learn More

neo-antigen
acting

Learn More

First-ever SP-Specific
Antibody Platform

Learn More

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™ platform is its Immucin™; lead immunotherapy product. After completion of a successful Phase-I/II in 15 multiple myeloma cancer patients, Vaxil’s Immucin™ was granted Orphan Drug Status by the FDA and EMA for that indication.

Vaxil - FDA Orphan Drug Status

Vaxil’s Lead Immunotherapy Immucin™ Obtains Orphan Drug Status from FDA and EMA

logo-inmucin-slider